Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report

Circulation

Volumn 103, Issue 17, 2001, Pages 2213-2218

  Gotto Jr , Antonio M ^{a,b,c,d,e,f,g}  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

^e NOVARTIS   (Switzerland)

^f ASTRAZENECA   (United Kingdom)

^g BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; RESIN;

CHOLESTEROL METABOLISM; CLINICAL TRIAL; DOSE RESPONSE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 14344284525     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.17.2213     Document Type: Review

References (46)

1. Lamarche B, Lewis GF. Atherosclerosis prevention for the next decade: risk assessment beyond low density lipoprotein cholesterol. Can J Cardiol 1998;14:841-851.
2. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 1983;52:9B-12B.
3. Assmann G, ed. Lipld Metabolism Disorders and Coronary Heart Disease. Munich: MMV Medizin Verlag; 1993.
4. Brooks-Wilson A, Marcil M, Cell SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336-345.
5. Serfaty-Lacrosniere C, Civeira F, Lanzberg A, et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 1994;107:85-98.
6. Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res. 1998;39:1071-1078.
7. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 2000;101:1907-1912.
8. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis. 1996;121:1-12.
9. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
10. Freedman DS, Otvos JD, Jeyarah FJ, et al. Relation of lipoprotein sub-classes as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18: 1046-1053.
11. Glomset JA, Assmann G, Gjone E, et al. Lecithin:cholesterol acyltransferase deficiency and fish-eye disease. In: Scriver CR, Beaudet AL, Sly WS, el al, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw-Hill; 1995:1933-1951.
12. Breslow JL. Familial disorders of high-density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw-Hill; 1995:2031-2052.
13. Tall AR, Dammerman M, Breslow JL. Disorders of lipoprotein metabolism. In: Chien KR, ed. Molecular Basis of Cardiovascular Disease: A Companion to Braunwald's Heart Disease. Philadelphia: Saunders; 1999:413-427.
14. Huuskonen J, Ehnholm C. Phospholipid transfer protein in lipid metab-olism. Curr Opin Lipidol. 2000;11:285-289.
15. von Eckardstein A, Jauhiainen M, Huang Y, et al. Phospholipid transfer protein mediated conversion of high density lipoprotein generates pre beta 1-HDL. Biochim Biophys Acta. 1996;1301:255-261.
16. Jiang XC, Bruce C, Mar J, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest. 1999;103:907-914.
17. Qin S, Kawano K, Bruce C, et al. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV rich lamellar lipoproteins. J Lipid Res. 2000;41:269-276.
18. Rader DJ. Lipid disorders. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven; 1998:59-90.
19. Kozarsky KF, Donahee MH, Rigotti A, et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997;387:414-417.
20. Landschulz KT, Pathak RK, Rigotti A, et al. Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Biol Chem. 1997;272:13242-13249.
21. Trigatti B, Rayburn H, Vinals M, et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA. 1999;96:9322-9327.
22. Kozarsky KF, Donahee MH, Glick JM, et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol. 2000;20:721-727.
23. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
24. Graham A, Hassall DG, Rafique S, et al. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 1997;135:193-204.
25. Myers DE, Huang WN, Larkins RG. Lipoprotein-induced prostacyclin production in endothelial cells and effects of lipoprotein modification. Am J Physiol. 1996;271:C1504-C1511.
26. National Cholesterol Education Program Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
27. Crouse SF, O'Brien BC, Grandjean PW, et al. Training intensity, blood lipids, and apolipoproteins in men with high cholesterol. J Appl Physiol. 1997;82:270-277.
28. Spate-Douglas T, Keyser RE. Exercise intensity: its effect on the high-density lipoprotein profile. Arch Phys Med Rehabil. 1999;80:691-695.
29. Stone N, Blum C, Winston E. Management of Lipids in Clinical Practice. Caddo, Okla: Professional Communications Inc; 1997.
30. Martin-Jadraque R, Tato F, Mostaza JM, et al. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med. 1996;156:1081-1088.
31. Gibbons LW, Gonzales VBS, Gordon N, et al. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med. 1995;99:378-385.
32. Goldberg A, Alagona P, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85:1100-1105.
33. Jones P, Kafonek S, Laurora I, et al, for the CURVES Investigators. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587.
34. Frick MN, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
35. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21-27.
36. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
37. Shatara RK, Quest DW, Wilson TW. Fenofibrate lowers blood pressure in two genetic models of hypertension. Can J Physiol Pharmacol. 2000; 78:367-371.
38. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 1999;99:736-743.
39. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
40. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS). Circulation. 2000;101:477-484.
41. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA. 1998;280:605-613.
42. Rosenson RS. Low levels of high-density lipoprotein cholesterol (hypoal-phalipoproteinemia). Arch Intern Med. 1993;153:1528-1538.
43. The Scandinavian Simvastatin Survival Study (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344:1383-1389.
44. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
45. Harper CR, Jacobson TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 1999; 159:1049-1057.
46. Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol. 1992;2:23-28.